TY - JOUR
T1 - Cancer-associated venous thromboembolic disease, version 1.2015
T2 - Featured updates to the NCCN Guidelines
AU - Streiff, Michael B.
AU - Holmstrom, Bjorn
AU - Ashrani, Aneel
AU - Bockenstedt, Paula L.
AU - Chesney, Carolyn
AU - Eby, Charles
AU - Fanikos, John
AU - Fenninger, Randolph B.
AU - Fogerty, Annemarie E.
AU - Gao, Shuwei
AU - Goldhaber, Samuel Z.
AU - Hendrie, Paul
AU - Kuderer, Nicole
AU - Lee, Alfred
AU - Lee, Jason T.
AU - Lovrincevic, Mirjana
AU - Millenson, Michael M.
AU - Neff, Anne T.
AU - Ortel, Thomas L.
AU - Paschal, Rita
AU - Shattil, Sanford
AU - Siddiqi, Tanya
AU - Smock, Kristi J.
AU - Soff, Gerald
AU - Wang, Tzu Fei
AU - Yee, Gary C.
AU - Zakarija, Anaadriana
AU - McMillian, Nicole
AU - Engh, Anita M.
N1 - Publisher Copyright:
© JNCCN-Journal of the National Comprehensive Cancer Network.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of venous thromboembolism (VTE) in adult patients with a diagnosis of cancer or for whom cancer is clinically suspected. VTE is a common complication in patients with cancer, which places them at greater risk for morbidity and mortality. Therefore, risk-appropriate prophylaxis is an essential component for the optimal care of inpatients and outpatients with cancer. Critical to meeting this goal is ensuring that patients get the most effective medication in the correct dose. Body weight has a significant impact on blood volume and drug clearance. Because obesity is a common health problem in industrialized societies, cancer care providers are increasingly likely to treat obese patients in their practice. Obesity is a risk factor common to VTE and many cancers, and may also impact the anticoagulant dose needed for safe and effective prophylaxis. These NCCN Guidelines Insights summarize the data supporting new dosing recommendations for VTE prophylaxis in obese patients with cancer.
AB - The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of venous thromboembolism (VTE) in adult patients with a diagnosis of cancer or for whom cancer is clinically suspected. VTE is a common complication in patients with cancer, which places them at greater risk for morbidity and mortality. Therefore, risk-appropriate prophylaxis is an essential component for the optimal care of inpatients and outpatients with cancer. Critical to meeting this goal is ensuring that patients get the most effective medication in the correct dose. Body weight has a significant impact on blood volume and drug clearance. Because obesity is a common health problem in industrialized societies, cancer care providers are increasingly likely to treat obese patients in their practice. Obesity is a risk factor common to VTE and many cancers, and may also impact the anticoagulant dose needed for safe and effective prophylaxis. These NCCN Guidelines Insights summarize the data supporting new dosing recommendations for VTE prophylaxis in obese patients with cancer.
UR - http://www.scopus.com/inward/record.url?scp=84941770097&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941770097&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2015.0133
DO - 10.6004/jnccn.2015.0133
M3 - Article
C2 - 26358792
AN - SCOPUS:84941770097
SN - 1540-1405
VL - 13
SP - 1079
EP - 1095
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 9
ER -